A study for children with nearsightedness

Official Title: The Chaperone Study: A multi-center, double-masked, randomized, placebo-controlled, phase III study of the safety and efficacy of atropine 0.1% and 0.01% ophthalmic solutions administered with a microdose dispenser for the reduction of pediatric myopia progression


Is your child nearsighted?

Nearsightedness, or myopia, is a condition that results in blurry vision when looking at distant objects.

Myopia happens when the eyeball grows too long or the cornea (the clear front cover of the eye) is too curved.
As a result, light entering the eye is not focused correctly. While glasses and contact lenses can help a person with myopia see clearly, they do not address the underlying stretching of the eye.

Myopia detected in young children tends to increase through the school years . As myopia progresses, it can increase the risk of retinal detachment, cataracts, myopia maculopathy and even blindness. To date, FDA has not approved any drug therapies for reducing myopia progression.

This is why researchers are working to develop new medications and technologies that may help children and teens with this condition. The CHAPERONE Study is a research study testing the safety and effectiveness of microdosed atropine eye solution to see if it slows the progression of myopia in children.

Eligibility criteria:

- Is your child between 3-12 years old?
- Does your child need glasses to see distant objects?
- Is your child able to go to periodic visits at the study clinic to check his/her vision and overall eye health over a 4-year period (11 scheduled visits will be required)?
- Are you available to speak with study staff by phone periodically between your child’s clinic visits to review your child’s experience using study medication?

This study is not for children who have:
- Used atropine or other myopia drug therapies
- Had prior eye surgery
- A systemic disease or condition that can affect their vision

Contact Information

Chaperone Study Coordinator